GD-C Mission Statement
Promote high-quality care for people with glomerular diseases and stimulate opportunities to address gaps in knowledge, training, continuing education, and awareness across the spectrum of glomerular diseases.
Why focus on Glomerular Diseases?
Dr. Keisha Gibson, Chair of the ASN Glomerular Diseases Collaborative (GD-C), shares about the upcoming compendium currently in development. This resource will provide health care professionals with essential clinical resources and tools for caring for people with glomerular diseases. Stay tuned for its release!
GD-C Overview
The ASN GD-C Steering Committee will prioritize and design interventions to:
- improve early identification of persons with glomerular diseases to facilitate earlier treatment.
- expand clinical knowledge for improved recognition of GD and management.
- advocate for improved access to GD specialists and clinical trials as a treatment pathway.
- promote equal, optimal access to the best treatments, for all people with glomerular diseases.
Support for the Glomerular Diseases Collaborative is provided by Amgen, Otsuka America Pharmaceutical, Inc., Travere Therapeutics, Inc., and Vera Therapeutics, Inc.
